首页> 外文OA文献 >Differential expressions of PD-1, PD-L1 and PD-L2 between primary and metastatic sites in renal cell carcinoma
【2h】

Differential expressions of PD-1, PD-L1 and PD-L2 between primary and metastatic sites in renal cell carcinoma

机译:PD-1,PD-L1和PD-L2的差异表达肾细胞癌中的原发性和转移位点

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Abstract Background In clinical practice, the detection of biomarkers is mostly based on primary tumors for its convenience in acquisition. However, immune checkpoints may express differently between primary and metastatic tumor. Therefore, we aimed to compare the differential expressions of PD-1, PD-L1 and PD-L2 between the primary and metastatic sites of renal cell carcinoma (RCC). Methods Patients diagnosed with RCC by resection or fine needle aspiration of metastasis were included. Immunohistochemistry (IHC) was applied to detect PD-1, PD-L1 and PD-L2 expressions. SPSS 22.0 was applied to conduct Chi-square, consistency tests and Cox’s proportional hazards regression models. GraphPad Prism 6 was used to plot survival curves and R software was used to calculate Predictive accuracy (PA). Results In the whole cohort (N = 163), IHC results suggested a higher detection rate of PD-L1 in the metastasis than that of the primary site (χ2 = 4.66, p = 0.03), with a low consistent rate of 32.5%. Among different metastatic tumors, PD-1 was highly expressed in the lung/lymph node (65.3%) and poorly expressed in the brain (10.5%) and visceral metastases (12.5%). PD-L1 was highly expressed in lung/lymph node (37.5%) and the bone metastases (12.2%) on the contrary. In terms of survival analysis, patients with PD-1 expression either in the primary or metastasis had a shorter overall survival (OS) (HR: 1.59, 95% CI 1.08–2.36, p = 0.02). Also, PD-L1 expression in the primary was associated with a shorter OS (HR 2.55, 95% CI 1.06–6.15, p = 0.04). In the multivariate analysis, the predictive accuracy of the whole model for PFS was increased from 0.683 to 0.699 after adding PD-1. Conclusion PD-1, PD-L1 and PD-L2 were differentially expressed between primary and metastatic tumors. Histopathological examination of these immune check points in metastatic lesions of mRCC should be noticed, and its accurate diagnosis may be one of the effective ways to realize the individualized treatment.
机译:摘要背景下的临床实践中,生物标志物的检测主要基于原发性肿瘤,以便在收购方面的方便。然而,免疫检查点可以在原发性和转移性肿瘤之间表达不同。因此,我们旨在比较肾细胞癌(RCC)的主要和转移位点之间的PD-1,PD-L1和PD-L2的差异表达。方法包括通过切除或细针诊断rcc患者的患者。施用免疫组织化学(IHC)检测PD-1,PD-L1和PD-L2表达。 SPSS 22.0用于进行Chi-Square,一致性测试和Cox的比例危险回归模型。 GraphPad Prism 6用于绘制生存曲线,R软件用于计算预测精度(PA)。结果在整个队列(n = 163)中,IHC结果表明转移中PD-L1的较高检测率,而不是初级部位(χ2= 4.66,p = 0.03),其低一致率为32.5%。在不同的转移性肿瘤中,PD-1在肺/淋巴结(65.3%)中高度表达,并且在大脑(10.5%)和内脏转移中表达不良(12.5%)。 PD-L1在肺/淋巴结(37.5%)和骨转移中高度表达(12.2%)。在存活分析方面,在初级或转移中的PD-1表达患者较短的总存活(OS)(HR:1.59,95%CI 1.08-2.36,P = 0.02)。此外,初级的PD-L1表达与较短的OS(HR 2.55,95%CI 1.06-6.15,P = 0.04)相关。在多变量分析中,在添加PD-1后,PFS的整个模型的预测精度从0.683增加到0.699。结论PD-1,PD-L1和PD-L2在一次和转移性肿瘤之间差异表达。应当注意到MRCC转移性病变中这些免疫检查点的组织病理学检查,其准确诊断可能是实现个体化治疗的有效方法之一。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号